Revolution Medicines shares promising data around KRAS drug combination
Revolution Medicines has released promising Phase 1/2 clinical data for a KRAS drug combination targeting metastatic pancreatic cancer.
Velocity timeline
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Revolution Medicines presented Phase 1/2 clinical data at the ESMO Gastrointestinal Cancers Congress 2026. The results focus on Zoldonrasib combination regimens, specifically Zoldonrasib plus Daraxonrasib, for patients with RAS G12D metastatic pancreatic cancer in 2nd and 3rd line settings.
Coverage from Endpoints News, Yahoo Finance, and Oncodaily highlights the promising nature of the data. Medscape describes the findings as practice-changing for GI oncology, while WSAW notes the experimental drug provides additional time and hope for patients.
Future developments center on the application of these combination regimens within gastrointestinal oncology and the progression of the experimental drug's clinical timeline.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 1h ago.
Quick answers
What specific cancer is being targeted?
The data focuses on patients with RAS G12D metastatic pancreatic cancer.
Which drugs are being used in the combination?
The combination involves Zoldonrasib and Daraxonrasib.
Where was this data presented?
The data was presented at the ESMO Gastrointestinal Cancers Congress 2026.
Coverage (5)
- Anirban Maitra։ Data on Zoldonrasib Plus Daraxonrasib in 2nd and 3rd Line Metastatic Pancreatic Cancer Oncodaily · 1d ago
- Practice-Changing Data in GI Oncology Medscape · 1d ago
- Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 Yahoo Finance · 1d ago
- Experimental cancer drug brings time and hope for patients WSAW · 1d ago
- Revolution Medicines shares promising data around KRAS drug combination Endpoints News · 1d ago broke it first
People, places & organizations
Topics
Related trends
Grand Rapids oncologist says experimental pancreatic cancer drug showing promise in trials offers hope
An experimental drug targeting pancreatic cancer is showing promising survival gains in clinical trials.